Melvyn Tjon Joe Gin

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

Marieke E. Gimbel, Khalid Qaderdan, Laura M. Willemsen et al. · The Lancet · 2020 · 350 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

Clemens von Birgelen, Marlies M. Kok, Liefke C. van der Heijden et al. · The Lancet · 2016 · 248 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

Clemens von Birgelen, Hanim Sen, Ming Kai Lam et al. · The Lancet · 2013 · 198 citations

Medicine, Cardiology, Internal Medicine +15

Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations

Maarten J. Suttorp, J.Herre Kingma, Melvyn Tjon Joe Gin et al. · Journal of Thoracic and Cardiovascular Surgery · 1990 · 106 citations

Medicine, Cardiology, Pharmacology +16

Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions

Koen Teeuwen, René J. van der Schaaf, Tom Adriaenssens et al. · JACC: Cardiovascular Interventions · 2017 · 101 citations

Medicine, Cardiology, Surgery +16